Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 329

1.

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.

Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.

J Hepatol. 2007 Oct;47(4):499-505. Epub 2007 May 24.

PMID:
17560680
2.

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.

Sharma P, Kumar A, Shrama BC, Sarin SK.

Am J Gastroenterol. 2008 Jul;103(7):1689-97. doi: 10.1111/j.1572-0241.2008.01828.x. Epub 2008 Jun 28.

PMID:
18557715
3.

Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.

Fabrizi F, Dixit V, Messa P, Martin P.

Int J Artif Organs. 2009 Mar;32(3):133-40. Review.

PMID:
19440988
4.

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.

Hepatology. 2002 Oct;36(4 Pt 1):941-8.

PMID:
12297842
5.

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.

PMID:
11981339
6.

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.

J Gastroenterol Hepatol. 2002 Aug;17(8):882-8.

PMID:
12164964
7.

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.

Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.

J Gastroenterol Hepatol. 2003 Feb;18(2):152-6.

PMID:
12542598
8.

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.

Sagi SV, Mittal S, Kasturi KS, Sood GK.

J Gastroenterol Hepatol. 2010 May;25(5):880-5. doi: 10.1111/j.1440-1746.2009.06132.x. Epub 2010 Jan 14. Review.

PMID:
20074149
9.

Terlipressin and albumin combination treatment in hepatorenal syndrome.

Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.

Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccciii-cccv.

PMID:
15244209
10.

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators.

Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14.

PMID:
18471512
11.

Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.

Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.

Liver Int. 2013 Sep;33(8):1187-93. doi: 10.1111/liv.12179. Epub 2013 Apr 21.

PMID:
23601499
12.

Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.

Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.

Dig Dis Sci. 2008 Mar;53(3):830-5. Epub 2007 Oct 16.

PMID:
17939047
13.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
14.

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF.

Gastroenterology. 2002 Apr;122(4):923-30.

PMID:
11910344
15.

Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.

Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.

Dig Liver Dis. 2009 Apr;41(4):298-302. doi: 10.1016/j.dld.2008.09.014. Epub 2009 Jan 20.

PMID:
19158001
16.

The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.

Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K.

J Gastroenterol. 2012 Mar;47(3):313-20. doi: 10.1007/s00535-011-0485-8. Epub 2011 Oct 25.

PMID:
22038555
17.

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.

Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J.

J Hepatol. 2000 Jul;33(1):43-8.

PMID:
10905585
18.

[Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update].

Zhang ZF, Yang N, Zhao G, Liu LN, Wang YD, Duan ZJ.

Zhonghua Yi Xue Za Zhi. 2009 Jul 28;89(28):1970-4. Chinese.

PMID:
19950571
19.

Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.

Saner F, Kavuk I, Lang H, Biglarnia R, Frühauf NR, Schäfers RF, Malagó M, Broelsch CE.

Eur J Med Res. 2004 Feb 27;9(2):78-82.

PMID:
15090293
20.

Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.

Testro AG, Wongseelashote S, Angus PW, Gow PJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1535-40. Epub 2008 Sep 3.

PMID:
17784863

Supplemental Content

Support Center